Tectonic Therapeutic, Inc.
NASDAQ:TECXBiotechnology
-$0.29 today
- Market cap
- $411.32M
- Beta
- 1.22
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.45
Volume 0.17M
Average 0.20M
TECX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Tectonic Therapeutic, Inc.NASDAQ: TECX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $20.87M rose 60.1% year over year, behind the +63.7% change in trailing-twelve-month research & development. Sequentially, it rose 27.7% from the prior quarter. Over 3 fiscal years it compounded at +35.3% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +60.1% toward the trailing-twelve-month pace of +63.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 63.49M USD
- Year-over-year change
- +53.5%
- 4-year CAGR
- +55.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 63.49M | +53.5% |
| FY2024 | 2024-12-31 | 41.36M | +11.9% |
| FY2023 | 2023-12-31 | 36.97M | +44.1% |
| FY2022 | 2022-12-31 | 25.65M | +133.7% |
| FY2021 | 2021-12-31 | 10.98M | — |
Research & Development vs competitors
How TECX compares with its peers on the latest reported figures
- TECX's LTM Mar 2026 research & development of $71.32M is the lowest of the 4 companies compared; the peer median is $224.7M.
- Its year-over-year change of +63.7% is the 2nd highest of 4, against a peer median of +56.0%.
- Over three fiscal years its annual growth of +35.3% compares with a peer median of +83.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $294.44M | +79.9% | +83.9% | — | |
GENBGenerate Biomedicines, Inc. | FY2025 | $224.7M | +28.2% | — | 704.5% |
SEPNSepterna, Inc. | LTM Sep 2026 | $132.66M | +56.0% | — | 137.8% |
TECXTectonic Therapeutic, Inc. | LTM Mar 2026 | $71.32M | +63.7% | +35.3% | — |
| Peer median (excluding TECX) | $224.7M | +56.0% | +83.9% | 421.2% | |
Competitors are the stored peer set for TECX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 10.98M | 25.65M | 36.97M | 41.36M | 63.49M |
| Selling, General & Admin | 4.63M | 7.18M | 7.68M | 16.65M | 20.55M |
| Operating Expenses | 15.61M | 32.83M | 44.65M | 58.02M | 84.04M |
| Depreciation & Amortization | 364K | 1.01M | 1.48M | 1.65M | 1.38M |
| EBITDA | (8.12M) | (31.03M) | (41.19M) | (56.23M) | (71.48M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (15.61M) | (32.83M) | (44.65M) | (58.02M) | (84.04M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 149K | 581K | 4.26M | 11.3M |
| Interest Expense | 224K | 144K | 152K | 107K | 63K |
| Other Income / Expenses | 6.68M | 650K | 1.83M | 33K | 11.12M |
| Income Before Tax | (8.93M) | (32.18M) | (42.82M) | (57.98M) | (72.92M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.23M |
| Net Income | (8.93M) | (32.18M) | (42.82M) | (57.98M) | (74.15M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (33.36) | (29.05) | (11.59) | (3.93) | (4.05) |
| EPS (Diluted) | (33.36) | (29.05) | (11.53) | (3.93) | (4.05) |
| Weighted Avg Shares | 3.57M | 3.64M | 3.69M | 14.77M | 18.32M |
| Weighted Avg Shares (Diluted) | 3.57M | 3.64M | 3.71M | 14.77M | 18.32M |
Tectonic Therapeutic, Inc.
NASDAQ:TECX
Intrinsic Alpha fair value
Locked
Current Price
$21.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.